MA30718B1 - Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. - Google Patents
Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.Info
- Publication number
- MA30718B1 MA30718B1 MA31729A MA31729A MA30718B1 MA 30718 B1 MA30718 B1 MA 30718B1 MA 31729 A MA31729 A MA 31729A MA 31729 A MA31729 A MA 31729A MA 30718 B1 MA30718 B1 MA 30718B1
- Authority
- MA
- Morocco
- Prior art keywords
- yle
- pyridin
- derivatives
- immunomodulators
- specified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
DÉRIVÉS DE PYRIDIN-4-YLE DE FORMULE (I), DANS LAQUELLE A, R1, R2, R3, R4, R5, ET R6 SONT TELS QUE SPÉCIFIÉS DANS LA DESCRIPTION, AINSI QUE LEUR ÉLABORATION ET LEUR UTILISATION COMME COMPOSÉS PHARMACEUTIQUEMENT ACTIFS. CES COMPOSÉS AGISSENT EN PARTICULIER COMME AGENTS IMMUNOMODULATEURS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2006053147 | 2006-09-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30718B1 true MA30718B1 (fr) | 2009-09-01 |
Family
ID=38983600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31729A MA30718B1 (fr) | 2006-09-07 | 2009-03-18 | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. |
Country Status (27)
Country | Link |
---|---|
US (1) | US8580824B2 (fr) |
EP (1) | EP2069336B1 (fr) |
JP (1) | JP5253401B2 (fr) |
KR (1) | KR101470659B1 (fr) |
CN (1) | CN101511827B (fr) |
AR (1) | AR062683A1 (fr) |
AU (1) | AU2007292993B2 (fr) |
BR (1) | BRPI0716171B8 (fr) |
CA (1) | CA2661105C (fr) |
CL (1) | CL2007002593A1 (fr) |
CY (1) | CY1113727T1 (fr) |
DK (1) | DK2069336T3 (fr) |
ES (1) | ES2400533T3 (fr) |
HK (1) | HK1133654A1 (fr) |
HR (1) | HRP20130181T1 (fr) |
IL (1) | IL197393A (fr) |
MA (1) | MA30718B1 (fr) |
MX (1) | MX2009002233A (fr) |
MY (1) | MY149853A (fr) |
NO (1) | NO342156B1 (fr) |
NZ (1) | NZ576060A (fr) |
PL (1) | PL2069336T3 (fr) |
PT (1) | PT2069336E (fr) |
RU (1) | RU2447071C2 (fr) |
SI (1) | SI2069336T1 (fr) |
TW (1) | TWI392671B (fr) |
WO (1) | WO2008029371A1 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009002234A (es) * | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
CN101522645B (zh) * | 2006-09-21 | 2013-01-09 | 埃科特莱茵药品有限公司 | 苯衍生物及其免疫调节剂的用途 |
BRPI0720043A2 (pt) * | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
WO2008114157A1 (fr) * | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Dérivés d'amino-pyridine comme agonistes du récepteur s1p1/edg1 |
PL2195311T3 (pl) * | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
KR20100092473A (ko) * | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
WO2009109906A1 (fr) * | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Composés de pyridine |
JP2011513385A (ja) * | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
EP2262782B1 (fr) * | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés d'aminométhylbenzène |
BRPI0909055A2 (pt) * | 2008-03-07 | 2019-02-26 | Actelion Pharmaceuticals Ltd | composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto. |
CA2716448A1 (fr) | 2008-03-17 | 2009-09-24 | Patrick Brossard | Regime de dosage pour un agoniste selectif du recepteur s1p<sb>1</sb> |
TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
MX354134B (es) | 2008-07-23 | 2018-02-14 | Arena Pharm Inc | Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias. |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
US8389509B2 (en) | 2009-01-23 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted pyrazole compounds |
US8404672B2 (en) | 2009-01-23 | 2013-03-26 | Bristol-Meyers Squibb Company | Substituted heterocyclic compounds |
JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体 |
EP2403849B1 (fr) * | 2009-03-03 | 2014-07-16 | Merck Serono S.A. | Dérivés d'oxazole pyridine utiles comme agonistes du récepteur S1P1 |
CN102395564A (zh) * | 2009-04-17 | 2012-03-28 | 石原产业株式会社 | 2-卤代-6-取代-4-三氟甲基吡啶的生产方法 |
DE102009002514A1 (de) * | 2009-04-21 | 2010-10-28 | Evonik Degussa Gmbh | Verfahren zur Herstellung von substituierten 1,4-Chinonmethiden |
SI2454255T1 (sl) * | 2009-07-16 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-4-ila kot agonisti s1p1/edg1 |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
EP2528894A1 (fr) | 2010-01-27 | 2012-12-05 | Arena Pharmaceuticals, Inc. | Procédés de préparation d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
US8835470B2 (en) | 2010-04-23 | 2014-09-16 | Bristol-Myers Squibb Company | Mandelamide heterocyclic compounds |
JP5788507B2 (ja) | 2010-07-20 | 2015-09-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換3−フェニル−1,2,4−オキサジアゾール化合物 |
US9187437B2 (en) | 2010-09-24 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds |
US9133179B2 (en) * | 2011-01-19 | 2015-09-15 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl-derivatives |
SI2885266T1 (sl) | 2012-08-17 | 2020-10-30 | Actelion Pharmaceuticals Ltd | Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina |
UA115357C2 (uk) * | 2013-03-15 | 2017-10-25 | Ідорсія Фармасьютікалз Лтд | Похідні піридин-4-ілу |
EP3242666A1 (fr) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Procédés de traitement de maladies associées au récepteur s1p1 |
CN114573574A (zh) | 2015-05-20 | 2022-06-03 | 爱杜西亚药品有限公司 | 一种化合物的结晶形式 |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
WO2017004609A1 (fr) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Modulateurs thiadiazole de s1p et procédés de fabrication et d'utilisation |
WO2017004608A1 (fr) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Modulateurs d'oxadiazole de s1p, ainsi que procédés de fabrication et d'utilisation correspondants |
WO2017004610A1 (fr) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Agonistes de récepteur s1p1 économisant le s1p3 tercyclique |
US11534424B2 (en) | 2017-02-16 | 2022-12-27 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
CN107311994A (zh) * | 2017-08-14 | 2017-11-03 | 淄博职业学院 | 一种s1p‑1受体激动剂药物分子的新型合成方法 |
ES2964964T3 (es) | 2017-11-01 | 2024-04-10 | Bristol Myers Squibb Co | Compuestos bicíclicos puenteados como moduladores del receptor X farnesoide |
CN109956912B (zh) * | 2017-12-26 | 2021-10-22 | 中国医学科学院药物研究所 | 含二苯基噁二唑的羧酸类化合物、其制备方法及医药用途 |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
CA2051494C (fr) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones en tant qu'inhibiteurs de la captation du calcium |
DE4429465A1 (de) | 1994-08-19 | 1996-02-22 | Bayer Ag | Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde |
US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
DE19904389A1 (de) | 1999-02-04 | 2000-08-10 | Bayer Ag | Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe |
MXPA02001764A (es) | 1999-08-19 | 2004-03-19 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas de receptor de glutamato metabotropico. |
CN1853630A (zh) | 2001-02-21 | 2006-11-01 | Nps制药公司 | 杂多环化合物及其在亲代谢的谷氨酸受体拮抗剂中的应用 |
WO2003062252A1 (fr) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Agonistes du recepteur edg |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
EP1549640A4 (fr) | 2002-06-17 | 2008-08-06 | Merck & Co Inc | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg |
DE10237883A1 (de) * | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
WO2004035538A1 (fr) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Procede de fabrication de l'acide azetidine-3-carboxylique |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
EP1625123A4 (fr) | 2003-05-15 | 2007-08-29 | Merck & Co Inc | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles servant d'agonistes du recepteur s1p |
TW200505416A (en) | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
RU2390519C2 (ru) * | 2003-08-29 | 2010-05-27 | Оно Фармасьютикал Ко., Лтд. | Соединение, способное к связыванию с рецептором s1p, и его фармацевтическое применение |
CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物 |
AU2004299456B2 (en) * | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
US8022063B2 (en) | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
WO2006010379A1 (fr) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Nouveaux derives du thiophene utilises comme agents immunosupresseurs |
JP2008517915A (ja) * | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | S1p受容体アゴニストとしての2−(アリール)アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
CA2591399C (fr) | 2004-12-13 | 2014-05-20 | Ono Pharmaceutical Co., Ltd. | Derive d'acide aminocarboxylique et applications therapeutiques dudit derive |
WO2006100633A1 (fr) | 2005-03-23 | 2006-09-28 | Actelion Pharmaceuticals Ltd | Nouveaux derives de thiophene en tant qu'agonistes du recepteur de sphingosine-l-phosphate-1 |
MX2007011669A (es) | 2005-03-23 | 2007-11-15 | Actelion Pharmaceuticals Ltd | Nuevos derivados de tiofeno como agonistas del receptor de esfingosina-1-fosfato-1. |
KR101382733B1 (ko) | 2005-03-23 | 2014-04-14 | 액테리온 파마슈티칼 리미티드 | 면역조절물질로서의 수첨 벤조(c) 티오펜 유도체 |
NZ562468A (en) | 2005-04-05 | 2009-10-30 | Pharmacopeia Inc | Purine and imidazopyridine derivatives for immunosuppression |
CA2605594A1 (fr) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Compose heterocyclique |
AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
US20070043104A1 (en) | 2005-06-10 | 2007-02-22 | Luthman Ingrid K | UII-modulating compounds and their use |
KR20080024533A (ko) | 2005-06-24 | 2008-03-18 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
CN101203220A (zh) | 2005-06-28 | 2008-06-18 | 阿斯利康(瑞典)有限公司 | 新用途 |
AR057894A1 (es) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | Derivados de tiofeno |
TWI404706B (zh) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
ATE447568T1 (de) | 2006-01-24 | 2009-11-15 | Actelion Pharmaceuticals Ltd | Neue pyrinderivate |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
JP2009527501A (ja) | 2006-02-21 | 2009-07-30 | ユニバーシティ オブ バージニア パテント ファンデーション | S1p受容体アゴニストとしてのフェニル−シクロアルキル誘導体およびフェニル−複素環誘導体 |
AU2007251282A1 (en) | 2006-05-09 | 2007-11-22 | Pfizer Products Inc. | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AR061841A1 (es) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores. |
MX2009002234A (es) | 2006-09-08 | 2009-03-16 | Actelion Pharmaceuticals Ltd | Derivados de piridin-3-il como agentes inmunomoduladores. |
CN101522645B (zh) | 2006-09-21 | 2013-01-09 | 埃科特莱茵药品有限公司 | 苯衍生物及其免疫调节剂的用途 |
MX2009003129A (es) | 2006-09-29 | 2009-04-06 | Novartis Ag | Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras. |
JP2008120794A (ja) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | ヘテロ環化合物を含有する医薬組成物 |
US20080138955A1 (en) * | 2006-12-12 | 2008-06-12 | Zhiyuan Ye | Formation of epitaxial layer containing silicon |
BRPI0720043A2 (pt) | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
WO2008091967A1 (fr) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Composés chimiques |
WO2008114157A1 (fr) | 2007-03-16 | 2008-09-25 | Actelion Pharmaceuticals Ltd | Dérivés d'amino-pyridine comme agonistes du récepteur s1p1/edg1 |
PL2195311T3 (pl) | 2007-08-17 | 2011-08-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydynowe jako modulatory receptora S1P1/EDG1 |
KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
EP2222667B1 (fr) | 2007-12-10 | 2013-02-20 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés du thiophène |
WO2009109906A1 (fr) | 2008-03-06 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Composés de pyridine |
JP2011513385A (ja) | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
EP2262782B1 (fr) | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Nouveaux dérivés d'aminométhylbenzène |
BRPI0909055A2 (pt) | 2008-03-07 | 2019-02-26 | Actelion Pharmaceuticals Ltd | composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto. |
NZ589617A (en) | 2008-05-14 | 2012-06-29 | Scripps Research Inst | 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives |
SI2454255T1 (sl) | 2009-07-16 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-4-ila kot agonisti s1p1/edg1 |
-
2007
- 2007-09-06 PT PT78262870T patent/PT2069336E/pt unknown
- 2007-09-06 WO PCT/IB2007/053594 patent/WO2008029371A1/fr active Application Filing
- 2007-09-06 BR BRPI0716171A patent/BRPI0716171B8/pt active IP Right Grant
- 2007-09-06 PL PL07826287T patent/PL2069336T3/pl unknown
- 2007-09-06 CL CL200702593A patent/CL2007002593A1/es unknown
- 2007-09-06 SI SI200731169T patent/SI2069336T1/sl unknown
- 2007-09-06 JP JP2009527264A patent/JP5253401B2/ja active Active
- 2007-09-06 KR KR1020097006862A patent/KR101470659B1/ko active IP Right Grant
- 2007-09-06 ES ES07826287T patent/ES2400533T3/es active Active
- 2007-09-06 AR ARP070103940A patent/AR062683A1/es active IP Right Grant
- 2007-09-06 US US12/310,801 patent/US8580824B2/en active Active
- 2007-09-06 CA CA2661105A patent/CA2661105C/fr active Active
- 2007-09-06 TW TW096133280A patent/TWI392671B/zh active
- 2007-09-06 EP EP07826287A patent/EP2069336B1/fr active Active
- 2007-09-06 RU RU2009112538/04A patent/RU2447071C2/ru active
- 2007-09-06 DK DK07826287.0T patent/DK2069336T3/da active
- 2007-09-06 MY MYPI20090912A patent/MY149853A/en unknown
- 2007-09-06 NZ NZ576060A patent/NZ576060A/en not_active IP Right Cessation
- 2007-09-06 CN CN200780033152XA patent/CN101511827B/zh active Active
- 2007-09-06 AU AU2007292993A patent/AU2007292993B2/en not_active Ceased
- 2007-09-06 MX MX2009002233A patent/MX2009002233A/es active IP Right Grant
-
2009
- 2009-03-04 IL IL197393A patent/IL197393A/en active IP Right Grant
- 2009-03-18 MA MA31729A patent/MA30718B1/fr unknown
- 2009-04-06 NO NO20091394A patent/NO342156B1/no unknown
-
2010
- 2010-02-11 HK HK10101596.4A patent/HK1133654A1/xx not_active IP Right Cessation
-
2013
- 2013-02-27 CY CY20131100186T patent/CY1113727T1/el unknown
- 2013-03-04 HR HRP20130181TT patent/HRP20130181T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30717B1 (fr) | Derives de pyridin-3-yle en tant qu'agents immunomodulateurs | |
MA30718B1 (fr) | Derives de pyridin-4-yle en tant qu'agents immunomodulateurs. | |
MA30784B1 (fr) | Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs. | |
MA33528B1 (fr) | Derives pyridin-4-yliques | |
MA31988B1 (fr) | Derives d'aminopyrazole | |
MA32173B1 (fr) | Derives de pyridin-2-yle utilises comme agents immunomodulateurs | |
MA31906B1 (fr) | Inhibiteurs de la replication du virus de limmunodeficience humaine | |
MA31000B1 (fr) | Derives 2-aza-bicyclo[3.1.0]hexane | |
MA30231B1 (fr) | Derives de benzamides et d'heteroarenes | |
MA29909B1 (fr) | Derives de pyridazine | |
MA31703B1 (fr) | Dérivés pyridiniques utilisés comme modulateurs du récepteur s1p1/edg1 | |
MA32151B1 (fr) | Derives de 2-aza-bicyclo[2.2.1]heptane | |
TW200619199A (en) | 3-carbamoyl-2-pyridone derivatives | |
MA29550B1 (fr) | Derives de n- (pyridine-2-yl) - sulfonamide | |
MA30207B1 (fr) | Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide | |
MA33275B1 (fr) | Inhibiteurs de la replication du virus de l'immunodeficience humaine | |
MA31953B1 (fr) | Nouveaux derives du thiophene. | |
MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
MA29685B1 (fr) | Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques | |
MA32170B1 (fr) | Nouveaux derives d'aminomethylbenzene | |
BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA32711B1 (fr) | Pyrrolidine-2-carboxamides substitues | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif |